British Journal of Haematology

Papers
(The H4-Index of British Journal of Haematology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action345
COVID19 coagulopathy in Caucasian patients260
Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID‐19) infected patients249
Association between ABO blood groups and risk of SARS‐CoV‐2 pneumonia241
Autoimmune haemolytic anaemia associated with COVID‐19 infection228
Severe COVID‐19 infection and thrombotic microangiopathy: success does not come easily150
Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID‐19): a meta‐analysis129
Survival study of hospitalised patients with concurrent COVID‐19 and haematological malignancies127
COVID‐19‐associated immune thrombocytopenia126
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature117
COVID‐19 and ABO blood group: another viewpoint98
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID‐19): evidence of acute and sustained endothelial cell activation89
SARS‐CoV‐2‐induced remission of Hodgkin lymphoma89
Simultaneous onset of COVID‐19 and autoimmune haemolytic anaemia88
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma88
The association between severe COVID‐19 and low platelet count: evidence from 31 observational studies involving 7613 participants85
Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐ca84
Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic82
Azacitidine for patients with Vacuoles, E1 Enzyme, X‐linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry81
Poor outcome and prolonged persistence of SARS‐CoV‐2 RNA in COVID‐19 patients with haematological malignancies; King's College Hospital experience81
Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID‐19?80
COVID‐19 infection in patients with sickle cell disease78
Increased CD95 (Fas) and PD‐1 expression in peripheral blood T lymphocytes in COVID‐19 patients78
Updates on targeted therapies for acute myeloid leukaemia76
Clinical outcome of coronavirus disease 2019 in haemato‐oncology patients75
Acute aorto‐iliac and mesenteric arterial thromboses as presenting features of COVID‐1973
T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies71
Disseminated intravascular coagulation: epidemiology, biomarkers, and management68
Exacerbation of immune thrombocytopenia following COVID‐19 vaccination67
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations66
Dynamic relationship between D‐dimer and COVID‐19 severity65
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma64
Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series64
Impact of COVID‐19 on red blood cell rheology64
Machine learning and artificial intelligence in haematology62
Hemophagocytic lymphohistiocytosis‐like toxicity (carHLH) after CD19‐specific CAR T‐cell therapy62
Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity61
Guidelines on the use of irradiated blood components61
COVID‐19 infection and sickle cell disease: a UK centre experience60
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia60
Emicizumab treatment and monitoring in a paediatric cohort: real‐world data58
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID‐1957
More on COVID‐19 coagulopathy in Caucasian patients57
Prevalence of venous thromboembolism in critically ill patients with COVID‐1956
Molecular profiling in diffuse large B‐cell lymphoma: why so many types of subtypes?54
Endothelial cell function and endothelial‐related disorders following haematopoietic cell transplantation54
Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy54
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies54
First COVID‐19 maternal mortality in the UK associated with thrombotic complications54
Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells52
0.031080007553101